

Special Issue

Drug Resistance in COVID-19 Patients

Message from the Guest Editor

In recent times, the increase in Antimicrobial Resistance (AMR) has presented a daunting challenge to human and animal health. Different nations have united to fight against AMR as one of their highest priorities. They have agreed to implement several clinical and microbiological surveillance measures such as AMR stewardship programs, the promotion of rational and controlled antibiotics, and improved vaccination approaches, to name a few. Unfortunately, the ongoing COVID-19 pandemic has negatively affected the accessibility and technical capacity for diagnosis, treatment, and patient care of both COVID-19 and non-COVID-19 patients globally. Unwanted use of antibiotics is a critical factor of AMR. Although antibiotics are not an effective way to treat COVID-19, they have frequently been used during this pandemic. There is a growing concern that the COVID-19 pandemic may intensify AMR. In this Special Issue of Antibiotics, we invite original and review articles to deepen our insights into the AMR complication in COVID-19 patients as well as pathophysiologic mechanisms and treatment approaches for COVID-19 patients.

Guest Editor

Dr. Subhash Chand

Department of Anesthesiology, University of Nebraska Medical Center, Omaha, NE 68198, USA

Deadline for manuscript submissions

closed (31 October 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/71147

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)